Targeted antibody treatment for idiopathic pulmonary fibrosis
Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis
A new antibody drug designed to stick to and calm scarring in the lungs for people with idiopathic pulmonary fibrosis (IPF).
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vasarya Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project ID | NIH-11259230 on NIH RePORTER |
What this research studies
Researchers at Vasarya are developing VSR-H5, an antibody that selectively binds a unique marker only exposed in actively scarring lung tissue and spares healthy tissue. In the first phase they will improve the antibody's binding strength and remove safety liabilities to create a pool of candidate drugs. The team has already tested the tool compound on IPF patient lung samples and in multiple mouse models, showing reduced fibrosis and a clean toxicology profile so far. If those preclinical steps go well, the plan is to advance the leading candidates toward formal safety testing in people.
Who could benefit from this research
Good fit: Adults diagnosed with idiopathic pulmonary fibrosis, especially those with active or progressive scarring or who cannot tolerate current antifibrotic medications.
Not a fit: People without IPF, those with other unrelated lung diseases, or those whose lung damage is very advanced and irreversible would not be expected to benefit.
Why it matters
Potential benefit: If successful, this therapy could slow or stop lung scarring with fewer systemic side effects than current IPF drugs, potentially improving symptoms and survival.
How similar studies have performed: Approved IPF drugs provide only modest benefit and antibody approaches like this are largely experimental with encouraging lab and animal results but not yet proven in humans.
Where this research is happening
Camden, United States
- Vasarya Therapeutics, INC. — Camden, United States (Active)
Researchers
- Principal investigator: Hu, Ping — Vasarya Therapeutics, INC.
- Study coordinator: Hu, Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.